May 9 |
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates
|
May 9 |
Recursion Pharmaceuticals GAAP EPS of -$0.39 beats by $0.03, revenue of $13.79M beats by $0.72M
|
May 9 |
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
|
May 8 |
Recursion Pharmaceuticals Q1 2024 Earnings Preview
|
May 3 |
Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know
|
May 2 |
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
|
May 2 |
Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know
|
May 2 |
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
|
May 1 |
Recursion to Participate in Upcoming Investor Conferences
|
Apr 30 |
Jim Cramer is Recommending These 10 Stocks Heading Into May 2024
|